For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Ikena Oncology, Inc.

USPTO Granted Patents = 15

EPO Patents = 2

Trademarks = 2

Forward Citations = 18

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Alfredo C Castro (15 out of 114 patents)

Catherine Anne Evans (5 out of 44 patents)

Michael J Burke (4 out of 5 patents)

4. Sabine K Ruppel (2 out of 10 patents)

5. Karen J McGovern (2 out of 11 patents)

6. James Martin Nolan, Iii (2 out of 2 patents)

7. Sarah Jean Bethune (2 out of 2 patents)

8. Corinne Marie Folberth (2 out of 2 patents)

9. Thomas A Wynn (2 out of 2 patents)

10. Eric Haines (2 out of 2 patents)

11. Sergio L Santillana Soto (2 out of 2 patents)

12. Lan Xu (2 out of 3 patents)

13. Oksana Zavidij (2 out of 2 patents)

14. Iii James Martin Nolan (0 patent)

15 patents: Sort by Forward Citations

1. 12459895 - MEK inhibitors and uses thereof (2025-11-04),

2. 12162884 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitors (2024-12-10),

3. 12077542 - Indole AHR inhibitors and uses thereof (2024-09-03),

4. 12030876 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof (2024-07-09),

5. 11925651 - TEAD inhibitors and uses thereof (2024-03-12),

6. 11878958 - MEK inhibitors and uses thereof (2024-01-23),

7. 11760728 - Tead inhibitors and uses thereof (2023-09-19),

8. 11608329 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof (2023-03-21),

9. 11591339 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors (2023-02-28),

10. 11555026 - AHR inhibitors and uses thereof (2023-01-17),

11. 11458149 - TEAD inhibitors and uses thereof (2022-10-04),

12. 11358969 - Indole AHR inhibitors and uses thereof (2022-06-14),

13. 11274082 - Tead inhibitors and uses thereof (2022-03-15),

14. 10696650 - AHR inhibitors and uses thereof (2020-06-30),

15. 10689388 - Indole AHR inhibitors and uses thereof (2020-06-23),

Ikena Oncology is a biotechnology company focused on developing innovative cancer treatments. Their research and development efforts are centered around targeted therapies that have the potential to improve outcomes for patients with various types of cancer. Through strategic partnerships and collaborations, Ikena Oncology aims to bring novel therapies to market that address unmet medical needs in oncology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

15 Patents

#144 in Boston, MA

#1,231 in Massachusetts

#20,443 in US

#38,743 in the World

Boston, MA, United States of America

Ikena Oncology, Inc.

Forward Citations = 18

13 inventors:

Alfredo C Castro (15 out of 114 patents)

Catherine Anne Evans (5 out of 44 patents)

Michael J Burke (4 out of 5 patents)

4. Sabine K Ruppel (2 out of 10 patents)

5. Karen J McGovern (2 out of 11 patents)

Please report any incorrect information to support@idiyas.com

Loading…